News Conference News ACC 2024 PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE L.A. McKeown April 08, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup L.A. McKeown March 09, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT Yael L. Maxwell March 07, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery Todd Neale April 06, 2022
News Conference News ACC 2022 FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses Michael O'Riordan April 06, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2018 Salt in the Wound: Experts Clash Over Ideal Sodium Targets in Hypertension Michael O'Riordan March 15, 2018
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017